
TuHURA Biosciences, Inc. (HURA) Market Cap
TuHURA Biosciences, Inc. has a market capitalization of $185.6M.
Financials based on reported quarter end 2025-12-31
Price: $2.92
โผ -0.04 (-1.35%)
Market Cap: 185.65M
NASDAQ ยท time unavailable
CEO: James A. Bianco
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2013-02-22
Website: http://www.tuhurabio.com
TuHURA Biosciences, Inc. (HURA) - Company Information
Market Cap: 185.65M ยท Sector: Healthcare
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
Analyst Sentiment
Based on 3 ratings
Consensus Price Target
No data available
Price & Moving Averages
Related Companies in Healthcare

INOGEN INC (INGN)
Healthcare
$0.19B
Mkt Cap

CARTESIAN THERAPEUTICS INC (RNAC)
Healthcare
$0.19B
Mkt Cap

OMNIAB INC (OABI)
Healthcare
$0.19B
Mkt Cap

PROTALIX BIOTHERAPEUTICS INC (PLX)
Healthcare
$0.19B
Mkt Cap

TONIX PHARMACEUTICALS HOLDING CORP (TNXP)
Healthcare
$0.19B
Mkt Cap

NANO X IMAGING LTD (NNOX)
Healthcare
$0.18B
Mkt Cap
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"HURA reported $0.0 in revenue and a net loss of $6.8M, translating to EPS of -$0.13 for the quarter ended 2025-12-31. Net margin was therefore deeply negative, reflecting continued unprofitable operations. Free cash flow (FCF) was -$14.5M, driven by operating cash flow of -$14.4M, with only modest capex of -$0.05M. On the balance sheet, total assets were $27.4M versus $6.4M in total liabilities, resulting in $20.9M of equity. Net debt was -$3.1M, indicating net cash rather than leverage pressure from debt. Cash flow quality is the main concern: both operating cash flow and FCF were materially negative, and dividends are effectively zero (dividends paid of about $4k). With no stated buybacks, capital returns to shareholders appear limited. Valuation metrics and analyst targets were not provided, limiting valuation context. Market performance is highly volatile: the stock is down -44.3% over 1 year and -36.2% over 6 months, though YTD is reported +116.1%, which underscores sentiment swings rather than steady shareholder value creation. Overall, fundamentals show sustained losses despite a net-cash balance sheet, while shareholder returns reflect major price volatility."
Revenue Growth
Revenue is reported as $0.0 for the period, providing no evidence of top-line momentum or business scaling in the quarter. Drivers of revenue are not available in the dataset.
Profitability
Net income was -$6.8M with EPS of -$0.13, implying deeply negative profitability. Net margin cannot be meaningfully improved without revenue and/or cost optimization details.
Cash Flow Quality
Operating cash flow was -$14.4M and FCF was -$14.5M, indicating ongoing cash burn. Capex was minimal, and dividends were negligible, suggesting limited near-term shareholder cash returns.
Leverage & Balance Sheet
Balance sheet shows $27.4M assets and $6.4M liabilities, with $20.9M equity. Net debt of -$3.1M points to net cash, which can help buffer financial resilience despite losses.
Shareholder Returns
Total shareholder value creation looks weak based on capital appreciation and minimal dividends (about $4k paid). Despite YTD gains (+116.1%), the stock is down -44.3% over 1 year and -36.2% over 6 months, indicating negative longer-term momentum.
Analyst Sentiment & Valuation
Valuation metrics (P/E, FCF yield, ROE, debt/equity) and analyst price targets were not provided, limiting assessment. With persistent losses and negative FCF, valuation support is not evident from the provided data.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.